Types of implants of tenofovir alafenamide (TAF) for long-acting therapy currently under investigation
| Types of implant . | Drug release properties . |
|---|---|
| A subcutaneous silicone implant delivers TAF from orthogonal channels coated with polyvinyl alcohol. | It provides measurable plasma concentrations of TAF over more than 6 weeks and delivers TAF at near constant rate for up to 40 days after implantation.87 |
| A reservoir-style implant with an extruded tube of a biodegradable polymer [poly (ε-caprolactone)] membrane. | It can deliver TAF with sustained zero-order release kinetics. After subcutaneous injection, the biological fluid from the environment can enter and solubilize TAF, which is then passively transported across the membrane and released from the implant.88 |
| A subcutaneous implant formed with pressed TAF pellets and extruded polyurethane tubing. | This modular implant is tunable to adjust the rate and duration of TAF release through adjustment of geometry and membrane composition.89 |
| Types of implant . | Drug release properties . |
|---|---|
| A subcutaneous silicone implant delivers TAF from orthogonal channels coated with polyvinyl alcohol. | It provides measurable plasma concentrations of TAF over more than 6 weeks and delivers TAF at near constant rate for up to 40 days after implantation.87 |
| A reservoir-style implant with an extruded tube of a biodegradable polymer [poly (ε-caprolactone)] membrane. | It can deliver TAF with sustained zero-order release kinetics. After subcutaneous injection, the biological fluid from the environment can enter and solubilize TAF, which is then passively transported across the membrane and released from the implant.88 |
| A subcutaneous implant formed with pressed TAF pellets and extruded polyurethane tubing. | This modular implant is tunable to adjust the rate and duration of TAF release through adjustment of geometry and membrane composition.89 |
Types of implants of tenofovir alafenamide (TAF) for long-acting therapy currently under investigation
| Types of implant . | Drug release properties . |
|---|---|
| A subcutaneous silicone implant delivers TAF from orthogonal channels coated with polyvinyl alcohol. | It provides measurable plasma concentrations of TAF over more than 6 weeks and delivers TAF at near constant rate for up to 40 days after implantation.87 |
| A reservoir-style implant with an extruded tube of a biodegradable polymer [poly (ε-caprolactone)] membrane. | It can deliver TAF with sustained zero-order release kinetics. After subcutaneous injection, the biological fluid from the environment can enter and solubilize TAF, which is then passively transported across the membrane and released from the implant.88 |
| A subcutaneous implant formed with pressed TAF pellets and extruded polyurethane tubing. | This modular implant is tunable to adjust the rate and duration of TAF release through adjustment of geometry and membrane composition.89 |
| Types of implant . | Drug release properties . |
|---|---|
| A subcutaneous silicone implant delivers TAF from orthogonal channels coated with polyvinyl alcohol. | It provides measurable plasma concentrations of TAF over more than 6 weeks and delivers TAF at near constant rate for up to 40 days after implantation.87 |
| A reservoir-style implant with an extruded tube of a biodegradable polymer [poly (ε-caprolactone)] membrane. | It can deliver TAF with sustained zero-order release kinetics. After subcutaneous injection, the biological fluid from the environment can enter and solubilize TAF, which is then passively transported across the membrane and released from the implant.88 |
| A subcutaneous implant formed with pressed TAF pellets and extruded polyurethane tubing. | This modular implant is tunable to adjust the rate and duration of TAF release through adjustment of geometry and membrane composition.89 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
